Insider Buying: GSK plc (LON:GSK) Insider Acquires £19,725 in Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 1,500 shares of the stock in a transaction on Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.49) per share, for a total transaction of £19,725 ($24,739.75).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds purchased 7,150 shares of GSK stock. The shares were bought at an average price of GBX 1,394 ($17.48) per share, with a total value of £99,671 ($125,010.66).

GSK Trading Up 0.6 %

Shares of GSK stock opened at GBX 1,341.50 ($16.83) on Thursday. The firm has a market capitalization of £54.73 billion, a P/E ratio of 1,187.17, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a 1 year low of GBX 1,282.50 ($16.09) and a 1 year high of GBX 1,823.50 ($22.87). The firm’s fifty day simple moving average is GBX 1,382.54 and its 200 day simple moving average is GBX 1,503.06. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04.

GSK Announces Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, November 14th. This represents a dividend yield of 1.03%. GSK’s payout ratio is 5,309.73%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GSK shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,850 ($23.20) target price on shares of GSK in a report on Tuesday, September 3rd. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, December 11th. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Wednesday, August 28th. Finally, Berenberg Bank decreased their price target on shares of GSK from GBX 1,820 ($22.83) to GBX 1,600 ($20.07) and set a “buy” rating for the company in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.65).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.